TriviumVet

TriviumVet is an animal health research and development company dedicated to raising the standard of treatment for serious medical conditions in pets. The company focuses on developing novel veterinary drugs and diagnostics to address unmet needs and therapeutic gaps in companion animal medicine. TriviumVet identifies gaps in available treatments and has built a disruptive portfolio aimed at transforming existing standards of care across various therapeutic areas, including cardiology, renal disease, neuropathic pain, and gastrointestinal disorders.

One of TriviumVet's key therapeutic candidates is a novel veterinary formulation of rapamycin, a compound with potential benefits in prolonging health span, reducing cancer incidence, improving cognitive function, and reversing immune and cardiac decline in aging subjects. TriviumVet has developed a proprietary, delayed-release rapamycin formulation called Felycin for treating feline hypertrophic cardiomyopathy (HCM), a life-threatening condition affecting approximately 15% of cats.

In addition to its cardiology portfolio, TriviumVet is also actively engaged in clinical studies for chronic kidney disease (CKD) in cats. The company's feline CKD therapeutic candidate was deemed eligible for the FDA's expanded conditional approval pathway in October 2023, potentially accelerating its development and market availability.

TriviumVet has forged collaborations with prestigious research institutions, such as the Dog Aging Project, to further explore the potential of rapamycin for treating age-related diseases in companion animals. The company's RapaCat study, published in July 2023, demonstrated promising results for their feline HCM therapeutic candidate in preventing the progression of hypertrophy in client-owned cats with subclinical HCM.

In August 2022, TriviumVet appointed renowned veterinary cardiologist and researcher Dr. Joshua Stern to its Scientific Advisory Board, further strengthening its expertise in translational cardiology and cardiovascular genetics research.